Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss? – Nasdaq

24th August 2023

Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss? Nasdaq

OPUS IP on X (formerly Twitter)…

Twitter feed is not available at the moment.

RECENT PATENT NEWS…

Cognition Therapeutics receives patent for zervimesine form By Investing.com - Investing.com UK
UK explores IPO-led FRAND opinions in SEP licensing push - Managing Intellectual Property
Government sets out next steps on Standard Essential Patents - GOV.UK
A drug patent runs to 2045. FDA approval may allow up to five more years. - Stock Titan

UK BUSINESS NEWS…

Poundland in rescue talks as owners seek buyer
UK growth forecast upgraded but higher energy prices to hit economy next year
Phase Eight and Hobbs owner hit by cyber-attack, as H&M probes separate hack claim
Cost-of-living struggles inspire Community Cupboard

Designed by Industrial Action

Copyright © 2026 OPUS IP Limited. All Rights Reserved

OPUS IP Limited: COMPANY & OTHER LEGAL INFORMATION